We've got three new stocks to watch today:
Here's what you need to know...
We've liked Ford Motor Co. (NYSE: F) stock for a while. And after underperforming earlier in the year, Ford stock has gotten a nice bounce recently. It's up nearly 11% since Jim Hackett took over as CEO in late May.
Now there's another reason to buy...
Ford's premium pickup truck just became even more luxuriant. The 2018 Ford F-450 Super Duty Limited 4X4 will retail at as high as $94,455 for those who take all the options. And that's before taxes or title and registration fees.
The F-450 already has a sticker price of $77,461, substantially higher than the average pickup. The new Super Duty model can tow more than 30,000 pounds and includes two-tone leather seats with heating and cooling as well as massage capability.
Ford Marketing Manager Brian Rathsburg calls the new Super Duty Limited the "most luxurious, technologically advanced Super Duty ever."
Pickup trucks and SUVs are Ford's top sellers. Overall sales in September rose 9% from a year earlier, a total of 221,643 vehicles.
When Money Morning Executive Editor Bill Patalon talked about Ford back in January, he was especially excited about Hackett's leadership of the new Smart Mobility unit. Now that Hackett is running the company, he's in charge of driving the 114-year-old automaker into the next generation. On Tuesday afternoon, he outlined his new strategic plan, which includes investing heavily in electric cars and slashing $14 billion in costs over the next five years.
Currently, Ford's price-to-earnings ratio is just under 13, and the yield is nearly 5%. In other words, while its new truck may come with a high price tag, the stock may be trading at a discount.
An engineer from one of our favorite aerospace plays was awarded one of NASA's highest honors on Sept. 21.
The Silver Snoopy Award is given by NASA astronauts to employees and contractors who have "significantly contributed to the human space flight program to ensure flight safety and mission success."
Honoree Erica Raine works at Aerojet Rocketdyne Holdings Inc.'s (NYSE: AJRD) Redmond, Wash., facility. She was the lead engineer on a project that delivered eight auxiliary rocket engines for use on NASA's Orion spacecraft.
Eyeing 2022 for its first crewed mission, Orion could bring humans beyond Earth's orbit for the first time since the Apollo missions ended in the 1970s.
Alex Mathers, director of operations for the Redmond facility, was also nominated for the NASA Space Flight Awareness Management Award, in recognition of his leadership on the Orion program.
Must See: Marijuana stocks are seeing triple-digit gains, and the next wave of wealth is coming. Learn how you could turn a small $100 stake into a fortune. Read more...
California-based Aerojet also just received approval on a project that will add 700 new jobs in Huntsville, Ala. The $27-million expansion project includes plans for a defense business headquarters, a rocket shop business unit, and an advanced manufacturing facility.
Ramped-up tension between the United States and North Korea is one reason Aerojet is looking to expand. As Money Morning Global Energy Strategist Dr. Kent Moors wrote recently, Aerojet is a key provider for the Terminal High Altitude Area Defense (THAAD) program designed to shoot down missiles.
Aerojet is "front and center in what may be the most important defense niche," Kent said.
[mmpazkzone name="in-story" network="9794" site="307044" id="137008" type="4"]
Premium subscribers to Kent's paid Energy Advantage and weekly Energy Inner Circle investment research services had already seen double-digit gains from this pick before he recommended it to Money Morning readers on Aug. 17. Now the stock is up another 31% since then, compared to 4% for the S&P 500.
When we checked on Gilead Sciences Inc. (Nasdaq: GILD) in July, the stock appeared to be finally finding a bottom after dropping 50% in two years. Since then, GILD has been rising steadily, and Wall Street has taken notice.
Even after GILD had risen 14% in the previous month to $82, Forbes raised its rating from "Hold" to "Buy" on Sept. 21, and set a price target of $100. That was mostly thanks to the timely acquisition of Kite Pharma Inc. (Nasdaq: KITE) at the end of August - a move we said to look out for In July.
Lower prices and shorter treatment periods for hepatitis C drugs have weighed on Gilead's revenue. But the addition of Kite gives the company a cutting-edge new lymphoma treatment - one that attacks tumors by altering a patient's white blood cells - set for FDA approval later this year.
Money Morning Director of Technology & Venture Capital Research Michael Robinson wrote on July 10 that "Gilead is back in Wall Street's spotlight." He listed it as one of his top biotech bargains. That's already proving prescient, but it might not be a bargain much longer. Investors looking to hop on the bandwagon shouldn't delay.
Finally, here's our latest list of Money Morning Top 10 Outperformers:
Up Next: One gallon of this new "crystal fuel" could get you from New York to L.A. and back... seven times! Being hailed by many experts as energy's "Holy Grail," it's 1,693 times more powerful than the gasoline that runs your car. The mainstream investment media isn't even talking about it yet. Read more...
Follow Money Morning on Facebook, Twitter, and LinkedIn.